ProCE Banner Activity

ESR1 Mutations in Metastatic HR+ HER2- Breast Cancer: Testing and Treatment-Presented by Seth Wander, MD, PhD

Video

Seth Wander, MD, PhD, reviews ESR1 mutations in hormone receptor-positive (HR+) HER2-negative metastatic breast cancer, focusing on their role in breast cancer biology, patient outcomes, treatment decision-making, and clinical practice. The session will discuss the role of ESR1 mutations, current guidelines for ESR1 mutation testing and treatment, and the evolving treatment landscape. It will also highlight findings from major clinical trials involving patients with relapsed HR+ HER2-negative metastatic breast cancer, both with and without ESR1 mutations.

Released: February 19, 2025

Expiration: February 18, 2026

Sponsored By

Stemline

ProCE Banner

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Understand the role of ESR1 mutations in HR+ HER2- metastatic breast cancer biology

  • Review current guidelines for ESR1 mutation testing and treatment, and their clinical importance

  • Summarize the current treatment landscape and recent data updates from key clinical trials in patients with relapsed HR+ HER2- metastatic breast cancer, with or without ESR1 mutations, and discuss their implications for clinical practice and patient outcomes